Smartlab Europe

News

Breakthrough in how pancreatic cancer cells ingest nutrients points to new drug target

In a landmark cancer study published online in Nature, researchers at NYU School of Medicine have unraveled a longstanding mystery about how pancreatic tumor cells feed themselves, opening up new therapeutic possibilities for a notoriously lethal disease with...

Novartis drug Ilaris® approved by FDA to treat active systemic juvenile idiopathic arthritis

Novartis announced that the US Food and Drug Administration (FDA) has approved Ilaris® (canakinumab) for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older. Ilaris is the...

Boehringer Ingelheim joins Structural Genomics Consortium

Boehringer Ingelheim has joined the Structural Genomics Consortium (SGC). The consortium intends to promote research into protein structures and epigenetics that could pave the way for the development of novel therapies for previously uncurable diseases. ...

Bristol-Myers Squibb and Pfizer announce publication of ARISTOTLE subanalysis in Circulation

Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) announced that results from a prespecified subanalysis of the ARISTOTLE trial were published in Circulation, the peer-reviewed journal of the American Heart Association. Results...

Study opens new prospects for developing new targeted therapies for breast cancer

A study led by prominent breast cancer experts from Europe and the US has revealed a number of potentially important prospects for targeted therapies, and brings opportunities of truly personalised therapy for breast cancer a step closer, researchers...

Experts discuss ways to embed patient voices and values in clinical research

There is worldwide concern in the biomedical research community that enrollment in clinical trials is lagging, putting clinical research and consequent benefits to society in jeopardy. Experts explore ways to embed patient voices and...

Cancer studies often lack necessary rigor to answer key questions

Fueled in part by an inclination to speed new treatments to patients, research studies for cancer therapies tend to be smaller and less robust than for other diseases. This raises some questions about how...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »